Press release
Investigation announced for Investors in NASDAQ: FIXX shares over possible Wrongdoing at Homology Medicines, Inc.
An investigation on behalf of investors in Homology Medicines, Inc. (NASDAQ: FIXX) shares over potential wrongdoing.
Investors who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Homology Medicines directors breached their fiduciary duties and caused damage to the company and its shareholders.
Bedford, MA based Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
On July 21, 2020, a report was published questioning statements by Homology Medicines, Inc. and its officers about the efficacy of HMI-102, the Company’s lead product candidate for treatment of phenylketonuria. The report focused on Homology’s HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102’s lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, the report cited an email from Homology’s Chief Communications Officer appearing to indicate the Company’s awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.
Shares of Homology Medicines, Inc. (NASDAQ: FIXX) declined from $30.34 per share in March 2019 to as low as $9.19 per share on September 4, 2020.
Those who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in NASDAQ: FIXX shares over possible Wrongdoing at Homology Medicines, Inc. here
News-ID: 2228435 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Homology
Metachromatic Leukodystrophy Pipeline 2025: Pioneering Clinical Developments by …
DelveInsight's, "Metachromatic Leukodystrophy - Pipeline Insight, 2025," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Metachromatic Leukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Metachromatic Leukodystrophy (MLD) increasingly affecting populations worldwide and contributing…
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
The Key Phenylketonuria Companies in the market include - PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharmaceuticals, and others.
The Phenylketonuria market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Phenylketonuria pipeline products will significantly revolutionize the Phenylketonuria market dynamics.
DelveInsight's "Phenylketonuria Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as…
Hunter Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
The Hunter Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hunter Syndrome pipeline products will significantly revolutionize the Hunter Syndrome market dynamics.
DelveInsight's "Hunter Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United…
Phenylketonuria Market Is Projected to Grow Significantly During the Forecast Pe …
Phenylketonuria Market is anticipated to grow in the coming years owing to the rise in the cases of Phenylketonuria, growth in the research and development activities by the pharma and biotech giants for the development of novel drugs, and the expected launch of emerging therapies in the market.
Globally, several major pharma and biotech giants such as PTC Therapeutics, BioMarin Pharmaceuticals, Homology Medicines, and Synlogic are investigating their candidates for Phenylketonuria,…
Investigation announced for Long-Term Investors in shares of Homology Medicines, …
An investigation was announced for long-term investors in shares of Homology Medicines, Inc. (NASDAQ: FIXX) concerning potential breaches of fiduciary duties by certain directors of Homology Medicines, Inc..
Investors who are current long term investors in Homology Medicines, Inc. (NASDAQ: FIXX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors in shares of Homology Medicines, Inc. (NASDAQ: FIXX)
An investor, who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX), filed a lawsuit over alleged violations of Federal Securities Laws by Homology Medicines, Inc.
Investors who purchased shares of Homology Medicines, Inc. (NASDAQ: FIXX) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2022. NASDAQ: FIXX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Bedford, MA based Homology…
